Association of molecular subtypes with Ki-67 changes in untreated breast cancer patients undergoing pre-surgical trials.

ABSTRACT:

Background

Ki-67 is increasingly being used as a response biomarker in window of opportunity, pre-surgical trials for breast cancer patients. Since Ki-67 is often higher at surgery than at baseline core biopsy in subjects allocated to placebo, we investigated which factors affected this change.

Patients and methods

We retrieved data from 274 patients who received no active treatment in three consecutive pre-surgical trials from a single institution. We assessed the association between changes in Ki-67 from diagnostic biopsy to surgical specimen and the following factors: age, body mass index, tumor prognostic and predictive factors, including immunohistochemical molecular subtype, number and size of biopsy specimens, time from biopsy to surgery, circulating insulin-like grow

SUBMITTER: Gandini S 

PROVIDER: S-EPMC4433505 | biostudies-literature | 2014 Mar

REPOSITORIES: biostudies-literature